Phase 1 Safety Study of ALRN-5281 in Healthy Subjects

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

January 31, 2013

Primary Completion Date

May 31, 2013

Study Completion Date

May 31, 2013

Conditions

Growth Hormone Deficiency

Interventions

DRUG

ALRN-5281 0.015 mg/kg

DRUG

ALRN-5281 0.05 mg/kg

DRUG

ALRN-5281 0.15 mg/kg

DRUG

Placebo 0.015 mg/kg

DRUG

Placebo 0.05mg/kg

DRUG

Placebo 0.15mg/kg

Trial Locations (1)

Vince and Associates Clinical Research, LLC, Overland Park